Article
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Oncotarget - 17 Nov 2015
Hirano Toshiyuki, Yasuda Hiroyuki, Tani Tetsuo, Hamamoto Junko, Oashi Ayano, Ishioka Kota, Arai Daisuke, Nukaga Shigenari, Miyawaki Masayoshi, Kawada Ichiro, Naoki Katsuhiko, Costa Daniel B, Kobayashi Susumu S, Betsuyaku Tomoko, Soejima Kenzo
Abstract excerpt
EGFR mutated lung cancer accounts for a significant subgroup of non-small-cell lung cancer (NSCLC). Over the last decade, multiple EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been developed to target mutated EGFR. However, there is little information regarding mutation specific potency of EGFR-TKIs against various types of EGFR mutations. The purpose of this study is to establish an in vitro model to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.